In particular, IL-6 inhibitors have been reserved for use in treatment-resistant macular edema unresponsive to traditional therapies such as steroids, tumor necrosis factor alpha (TNF-alpha) inhibitors, or anti-VEGF inhibitors [1,6]. Here, IL6 is linked to macular retinal edema.